Effect of losartan on human platelets activation by thromboxane A2;Efecto del losartan sobre la activacion de plaquetas humanas por tromboxano A2

Revista Espanola de Cardiologia

Volumn 53, Issue 4, 2000, Pages 525-530

  Guerra, José I ^b   Montón, Mercedes ^b   Rodríguez Feo, Juan A ^b   Farré, Jerónimo ^b   Jiménez, Ana M ^b   Núñez, Antonio ^b   Gómez, Juan ^b   Rico, Luis ^b   Marcos, Pedro ^b   Castilla, Carlos ^b   Sánchez de Miguel, Lourdes ^b   Casado, Santos ^b   López Farré, Antonio ^b  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b NONE

Author keywords

Angiotensin; Platelets; Thrombosis; Thromboxane

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN; CAPTOPRIL; LOSARTAN; THROMBOXANE A2; ANGIOTENSIN II; IMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE; THROMBOXANE RECEPTOR;

ADULT; ARTICLE; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; DRUG BINDING; DRUG EFFECT; HUMAN; HUMAN CELL; MALE; THROMBOCYTE ACTIVATION; THROMBOSIS; PHYSIOLOGY;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ADULT; ANGIOTENSIN II; HUMANS; IMIDAZOLES; LOSARTAN; MALE; PLATELET ACTIVATION; RECEPTORS, THROMBOXANE; TETRAZOLES; THROMBOXANE A2;

EID: 0034117103     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-8932(00)75123-2     Document Type: Article

References (23)

1. Timmermans PBWM, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45: 205-251.
2. Johnston CI. Angiotensin receptor antagonists: focus on losartan. Lancet 1995; 346: 1403-1407.
3. Wong PC, Price WA, Chiu AT, Duncia JV, Carini DJ, Wexler RR et al. Nonpeptide angiotensin II receptor antagonist. VIII. Characterization of functional antagonist displayed by DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990; 252: 719-725.
4. Pitt B, Segal R, Martínez FA, Meurers G, Cowley AJ, Thomas I et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747-752.
5. Hammon JW, Oates JA, Interaction of platelets with the vessel wall in the pathophysiology of sudden cardiac death. Circulation 1986; 73: 224-226.
6. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci 1975; 72: 2294-2298.
7. Patrono C, Renda G. Platelet activation and inhibition in unstable coronary syndromes. Am J Cardiol 1997; 80: 17E-20E.
8. López-Farré A, Farré J, Sánchez de Miguel L, Romero J, Gómez J, Rico L et al. Trombosis y enfermedad coronaria: neutrófilos, óxido nítrico y aspirina. Rev Esp Cardiol 1998; 51: 171-177.
9. Li P, Ferrario CM, Brosnihan KB. Nonpeptide angiotensin II antagonist losartan inhibits thromboxane A2-induced contractions in canine coronary arteries. J Pharmacol Exp Ther 1997; 281: 1065-1070.
10. Bertolino F, Valentín JP, Maffre M, Jover B, Bessac AM, John GW. Prevention of thromboxane A2 receptor-mediated pulmonary hypertension by a nonpeptide angiotensin II type 1 receptor antagonist. J Pharmacol Exp Ther 1994; 268: 747-752.
11. Sánchez de Miguel L, Casado S. Farré J, García-Durán M, Rico L, Montón M et al. Comparison of in vitro effects of trifusal and acetylsalicilic acid on nitric oxide synthesis by human neutrophils. Eur J Pharmacol 1998; 343: 57-65.
12. López-Farré A, Riesco A, Digiuni E, Mosquera JR, Caramelo C, Sánchez de Miguel L et al. Aspirin-stimulated nitric oxide production by neutrophils after acute myocardial ischemia in rabbits. Circulation 1996; 94: 83-87.
13. 2 receptor antagonists. Thromb Res 1986; 41: 471-481.
14. Corriu C, Bernard S, Schott C, Stoclet JC. Effects of losartan on contractile responses of conductance and resistance arteries from rats. J Cardiovasc Pharmacol 1995; 26: 688-692.
15. Sweet DS, Bradstreet DC, Berman RS, Jallard N, Saenz A, Weidler DJ. Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension. Am J Hypertens 1994; 7: 1035-1040.
16. Burrell LM, Johnston CI. Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease. Drugs Aging 1997; 10: 421-434.
17. López-Farré A, Caramelo C, Esteban A, Alberola ML, Millás I, Montón M et al. Effects of aspirin on platelets-neutrophil interactions. Role of nitric oxide and endothelin-1. Circulation 1995; 91: 2080-2088.
18. Marcus AJ, Safier LB. Thromboregulation: multicellular modulation of platelet reactivity in hemostasis and thrombosis. FASEB J 1993; 7: 516-522.
19. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991; 43: 109-141.
20. Crabos M, Bertschin S, Búhler FR, Rogg H, Evéquoz D, Eberhard M et al. Identification of AT-1 receptors on human platelets and decreased angiotensin II binding in hypertension. J Hypertension 1993; 11: 5230-5231.
21. Moore TJ, Williams GH. Angiotensin II receptors on human platelets. Circ Res 1981; 51: 314-320.
22. Ding YA, Maclntyre DE, Kenyon CJ, Semple PF. Angiotensin II effects on platelet function. J Hypertens 1985; 3: S251-S253.
23. Burnier M, Centeno G, Grouzmann E, Walker P, Waeber B, Brunner HR. In vitro effects of DuP 753, a nonpeptide angiotensin II receptor antagonist, on human platelets and rats vascular smooth muscle cells. Am J Hypertension 1991; 4: 438-443.